A Retrospective Cohort Study of SARS-CoV-2 Mortality Rate in Individuals with Opioid Use Disorder in Ilam (Southwest of Iran)

Background & Objective: Individuals with opioid use disorder are a marginalized population in any society. They commonly have a weaker immune system, greater stress vulnerability, poorer health, more high-risk behaviors, and less access to healthcare services compared to the general population, which can expose them to a risk of severe COVID-19 complications. This study aimed to evaluate the effects of opioid use disorder on mortality in patients with SARS-CoV-2. Materials & Methods: This registry-based retrospective cohort study was conducted on 2362 consecutive inpatients with a confirmed diagnosis of SARS-CoV-2 between March 5, 2020 and March 21, 2021, presenting to a university hospital in Ilam in the southwest of Iran. Forty-five patients with opioid use disorder were identified in this study and matched to 100 patients without opium addiction. All patients with a history of opium addiction were included in the study group, and age-and sex-matched patients without opioid use disorder were randomly recruited as the controls. After adjusting for the effects of age and comorbidities, data were analyzed in STATA version 10, using logistic regression models. Results: The mortality of patients with opioid use disorder increased following COVID-19 (adjusted OR: 6.59;95% CI: 1.84–23.59;P=0.004). Hypertension (adjusted OR: 8.17;95% CI: 2.21–30.15;P=0.002) and advancing age (OR: 1.06;95% CI: 1.01–1.11;P=0.01) were significantly associated with increased COVID-19 mortality. Conclusion: Based on the present findings, opioid use disorder is a possible risk factor for mortality following COVID-19. The findings of the present study can be applied in the implementation of preventive measures and policies and prioritization of COVID-19 vaccination. However, further relevant research is recommended.

[1]  F. Qeadan,et al.  Opioid use disorder and health service utilization among COVID-19 patients in the US: A nationwide cohort from the Cerner Real-World Data , 2021, EClinicalMedicine.

[2]  O. Mehrpour,et al.  A double-edged sword of using opioids and COVID-19: a toxicological view , 2020, Substance Abuse Treatment, Prevention, and Policy.

[3]  Noel S. Weiss,et al.  COVID-19 mortality risk for older men and women , 2020, BMC Public Health.

[4]  J. Bae,et al.  COVID-19 and diabetes mellitus: from pathophysiology to clinical management , 2020, Nature Reviews Endocrinology.

[5]  N. Volkow,et al.  Correction: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.

[6]  N. Volkow,et al.  COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.

[7]  Saad Al-Ezzi COVID -19 pandemic is a worldwide typical Biopsychosocial crisis , 2020 .

[8]  A. Munasinghe,et al.  SARS-CoV-2 and the pandemic of COVID-19 , 2020, Postgraduate Medical Journal.

[9]  M. Eslami,et al.  COVID-19 pandemic and addiction: Current problems in Iran , 2020, Asian Journal of Psychiatry.

[10]  D. Lewis,et al.  COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives , 2020, Nature Reviews Cardiology.

[11]  S. Dubey,et al.  COVID-19 and addiction , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[12]  J. Perrone,et al.  Opioid Use Disorder and COVID-19: Crashing of the Crises , 2020, Journal of addiction medicine.

[13]  Arul James,et al.  Basic Opioid Pharmacology — An Update , 2020, British journal of pain.

[14]  O. Mehrpour,et al.  The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms , 2020, Substance Abuse Treatment, Prevention, and Policy.

[15]  T. Clausen,et al.  COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper , 2020, Basic and clinical neuroscience.

[16]  Xiliang Wang,et al.  COVID-19: a new challenge for human beings , 2020, Cellular & Molecular Immunology.

[17]  C. Jolley,et al.  COPD and asthma in patients with opioid dependency: a cross-sectional study in primary care , 2020, npj Primary Care Respiratory Medicine.

[18]  Susan S Salmond,et al.  A Population Health Approach to America's Opioid Epidemic , 2019, Orthopedic nursing.

[19]  J. Moyano,et al.  Opioids in the immune system: from experimental studies to clinical practice. , 2019, Revista da Associação Médica Brasileira.

[20]  D. Satre,et al.  Alcohol, Cannabis, and Opioid Use Disorders, and Disease Burden in an Integrated Health Care System. , 2017, Journal of addiction medicine.

[21]  P. Austin,et al.  Incident opioid drug use and adverse respiratory outcomes among older adults with COPD , 2016, European Respiratory Journal.

[22]  P. Sacerdote,et al.  Opioids and immune system , 2006, Palliative medicine.